Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    146
    ...
ATC Name B/G Ingredients Dosage Form Price
N02BE01 ADOL G Paracetamol - 500mg 500mg Caplet 81,974 L.L
N02BE01 DOLOPAN G Paracetamol - 500mg 500mg Tablet, film coated 135,664 L.L
N02BE01 DOLOPAN G Paracetamol - 500mg 500mg Tablet, film coated 317,403 L.L
N02BE01 DOLOPAN G Paracetamol - 500mg 500mg Tablet, film coated 380,115 L.L
N02BE01 DOLOPAN G Paracetamol - 500mg 500mg Tablet, film coated 317,403 L.L
N02BE01 FEBRADOL G Paracetamol - 500mg 500mg Tablet 327,642 L.L
N02BE01 NOMAL G Paracetamol - 500mg 500mg Tablet 305,884 L.L
N02BE01 PAINOL G Paracetamol - 500mg 500mg Tablet 95,989 L.L
N02BE01 PARACETAMOL G Paracetamol - 500mg 500mg Tablet 1,873,700 L.L
N02BE01 PARACETAMOL G Paracetamol - 500mg 500mg Tablet 66,552 L.L
N02BE01 PARACETAMOL G Paracetamol - 500mg 500mg Tablet 3,161,230 L.L
N02BE01 PANADOL JOINT B Paracetamol - 665mg 665mg Tablet, film coated, prolonged release 291,614 L.L
N02BE01 FEBRADOL JOINT G Paracetamol - 665mg 665mg Tablet 289,246 L.L
N02BE01 DOLIPRANE B Paracetamol - 1,000mg 1000mg Tablet 120,946 L.L
N02BE01 DOLIPRANE B Paracetamol - 1000mg 1000mg Tablet 120,946 L.L
N02BE01 EFFERALGAN B Paracetamol - 1g 1g Tablet, film coated 129,009 L.L
N02BE01 PARACETAMOL ARROW G Paracetamol - 1g 1g Tablet 80,631 L.L
N02BE01 SICADOL G Paracetamol - 1000mg 1000mg Tablet 423,310 L.L
N02BE01 TYLENOL B Paracetamol - 100mg 100mg Suppository 190,826 L.L
N02BE01 SULDEX B G Paracetamol - 150mg 150mg Suppository 117,746 L.L
N02BE01 TYLENOL B Paracetamol - 200mg 200mg Suppository 235,172 L.L
N02BE01 ADOL G Paracetamol - 250mg 250mg Suppository 124,977 L.L
N02BE01 ALGIVIC G Paracetamol - 250mg 250mg Suppository 215,015 L.L
N02BE01 PARA-DENK 250 SUPPOS. G Paracetamol - 250mg 250mg Suppository 190,826 L.L
N02BE01 PARA-DENK 250 SUPPOS. G Paracetamol - 250mg 250mg Suppository 190,826 L.L
N02BE01 SULDEX 250 G Paracetamol - 250mg 250mg Suppository 127,985 L.L
N02BE01 ADOL G Paracetamol - 500mg 500mg Suppository 131,697 L.L
N02BE01 ALGIVIC G Paracetamol - 500mg 500mg Suppository 147,183 L.L
N02BE01 SULDEX A G Paracetamol - 600mg 600mg Suppository 200,936 L.L
N02BE01 ADOL G Paracetamol - 125mg 125mg Suppository 107,507 L.L
    ...
    146
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025